March 22, 2013

PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report

Key Points

Key points are not available for this paper at this time.

Abstract

ARMSn has an outcome similar to ERMS and superior EFS compared to ARMS with either P3F or P7F, when given therapy designed for children with intermediate risk RMS. This prospective analysis supports incorporation of PAX-FOXO1 fusion status into risk stratification and treatment allocation.

Bookmark

Cite This Study

Skapek et al. (Fri,) studied this question.

synapsesocial.com/papers/69d8a74c1dfc3877cabedb79 https://doi.org/https://doi.org/10.1002/pbc.24532

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Inconvenience of Convenience Cohorts: Rhabdomyosarcoma and the <i>PAX-FOXO1</i> Biomarker2012 · 31 citations
2<i>PAX3/FOXO1</i> Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification2012 · 360 citations
3Fusion-Negative Alveolar Rhabdomyosarcoma: Modification of Risk Stratification Is Premature2010 · 20 citations
4Prognostic value of PAX–FKHR fusion status in alveolar rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma study group (CWS)2011 · 75 citations
5Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative Groups2008 · 473 citations

Bookmark